We investigated whether serum bilirubin level (a marker of heme oxygenase activity) is a predictor of thrombus burden in patients with acute myocardial infarction. Patients (n = 229; male 72.9%; mean age 63 ± 13.4 years) who were admitted with ST-segment elevation myocardial infarction (STEMI) were enrolled. Patients were divided into 2 groups. Group 1 was defined as low thrombus burden and group 2 was defined as high thrombus burden. Patients with high thrombus burden had higher total bilirubin levels (14.4 [4.3-22.9] vs 7.7 [2.4-20.3] µmol/L, P ≤ .001), (0.84 [0.25-1.34] vs 0.45 [0.14-1.19] mg/dL P ≤ .001) and direct bilirubin levels (3.1 [2.1-8.4] vs 1.7 [0.5-6.5] µmol/L, P ≤ .001), (0.18 [0.03-0.49] vs 0.10 [0.03-0.38] mg/dL, P ≤ .001). At multivariate analysis, total bilirubin (odds ratio: 1.05, 95% confidence interval: 1.03-1.08, P ≤ .001) was the independent predictor of high thrombus burden. In conclusion, total bilirubin level is independently associated with high thrombus burden in patients with STEMI.
YipHKChenMCChangHW. Angiographic morphologic features of infarct-related arteries and timely reperfusion in acute myocardial infarction: predictors of slow-flow and no-reflow phenomenon. Chest. 2002;122(4):1322–1332.
2.
SinghMLennonRJHolmesDRJrBellMRRihalCS. Correlates of procedural complications and a simple integer risk score for percutaneous coronary intervention. J Am Coll Cardiol. 2002;40(3):387–393.
3.
HenriquesJPZijlstraFOttervangerJP. Incidence and clinical significance of distal embolization during primary angioplasty for acute myocardial infarction. Eur Heart J. 2002;23(14):1112–1117.
4.
FokkemaMLVlaarPJSvilaasT. Incidence and clinical consequences of distal embolization on the coronary angiogram after percutaneous coronary intervention for ST-elevation myocardial infarction. Eur Heart J. 2009;30(8):908–915.
5.
XuYQuXFangWChenH. Prevalence, correlation and clinical outcome of intra-procedural stent thrombosis in patients undergoing primary percutaneous coronary intervention for acute coronary syndrome. J Interv Cardiol. 2013;26(3):215–220.
6.
De LucaGSuryapranataHStoneGW. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA. 2005;293(14):1759–1765.
7.
De LucaGNavareseEMarinoP. Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a metaregression analysis of randomized trials. Eur Heart J. 2009;30(22):2705–2713.
8.
CostopoulosCGorogDADi MarioCKukrejaN. Use of thrombectomy devices in primary percutaneous coronary intervention: a systematic review and meta-analysis. Int J Cardiol. 2013;163(3):229–241.
9.
GhemCSarmento-LeiteREde QuadrosASRossettoSGottschallCA. Serum bilirubin concentration in patients with an established coronary artery disease. Int Heart J. 2010;51(2):86–91.
10.
SchwertnerHAJacksonWGTolanG. Association of low serum concentration of bilirubin with increased risk of coronary artery disease. Clin Chem. 1994;40(1):18–23.
11.
OkuharaKKisakaTOzonoR. Change in bilirubin level following acute myocardial infarction is an index for heme oxygenase activation. South Med J. 2010;103(9):876–881.
12.
SahinOAkpekMElcikD. Bilirubin levels and the burden of coronary atherosclerosis in patients with STEMI. Angiology. 2013;64(3):200–204.
13.
CelikTKayaMGAkpekMYarliogluesMSarliBTopsakalR. Does serum bilirubin level on admission predict TIMI flow grade and in-hospital MACE in patients with STEMI undergoing primary PCI. Angiology. 2014;65(3):198–204.
14.
GibsonCMde LemosJAMurphySA. Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy. Circulation. 2001;103(21):2550–2554.
15.
TanbogaIHTopcuSAksakalEKalkanKSevimliSAcikelM. Determinants of angiographic thrombus burden in patients with ST-segment elevation myocardial infarction. Clin Appl Thromb Hemost. 2014;20(7):716–722.
16.
BaltaSCelikTMikhailidisDP. The relation between atherosclerosis and the neutrophil-lymphocyte ratio[published online February 19, 2015]. Clin Appl Thromb Hemost. 2015. pii:1076029615569568.
17.
AkpekMKayaMGLamYY. Relation of neutrophil/ lymphocyte ratio to coronary flow to in-hospital major adverse cardiac events in patients with ST-elevated myocardial infarction undergoing primary coronary intervention. Am J Cardiol. 2012;110(5):621–627.
18.
HanYCYangTHKimDI. Neutrophil to lymphocyte ratio predicts long-term clinical outcomes in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Korean Circ J. 2013;43(2):93–99.
19.
AkpekMElcikDKalayNYarliogluesMDogduOSahinO. The prognostic value of serum gamma glutamyl transferase activity on admission in patients with STEMI undergoing primary PCI. Angiology. 2013;63(8):579–585.
20.
TenhunenRMarverHSSchmidR. The enzymatic conversion of heme to bilirubin by microsomal heme oxygenase. Proc Natl Acad Sci U S A. 1968;61(2):748–755.
21.
TenhunenRMarverHSSchmidR. Microsomal heme oxygenase. Characterization of the enzyme. J Biol Chem. 1969;244(23):6388–6394.
22.
MainesMDTrakshelGMKuttyRK. Characterization of two constitutive forms of rat liver microsomal heme oxygenase. Only one molecular species of the enzyme is inducible. J Biol Chem. 1986;261(1):411–419.
23.
McCoubreyWKJrHuangTJMainesMD. Isolation and characterization of a cDNA from the rat brain that encodes hemoprotein heme oxygenase-3. Eur J Biochem. 1997;247(2):725–732.
24.
ShibaharaSYoshizawaMSuzukiHTakedaKMeguroKEndoK. Functional analysis of cDNAs for two types of human heme oxygenase and evidence for their separate regulation. J Biochem. 1993;113(2):214–218.
25.
BreimerLHMikhailidisDP. Could carbon monoxide and bilirubin be friends as well as foes of the body?Scand J Clin Lab Invest. 2010;70(1):1–5.
26.
SerdarZSerdarAAltinAEryilmazUAlbayrakS. The relation between oxidant and antioxidant parameters and severity of acute coronary syndromes. Acta Cardiol. 2007;62(4):373–380.
27.
AmanvermezRAcarEGunayMBaydınAYardanTBekY. Hsp 70, hsCRP and oxidative stress in patients with acute coronary syndromes. Bosn J Basic Med Sci. 2012;12(2):102–107.
28.
YanoYOzonoROishiYKambeMYoshizumiMIshidaT. Genetic ablation of the transcription repressor Bach1 leads to myocardial protection against ischemia/reperfusion in mice. Genes Cells. 2006;11(7):791–803.
29.
MeloLGAgrawalRZhangL. Gene therapy strategy for long-term myocardial protection using adeno-associated virus mediated delivery of heme oxygenase gene. Circulation. 2002;105(5):602–607.
30.
YetSFTianRLayneMD. Cardiac-specific expression of heme oxygenase-1 protects against ischemia and reperfusion injury in transgenic mice. Circ Res. 2001;89(2):168–173.
31.
GriendlingKKFitzGeraldGA. Oxidative stress and cardiovascular injury: part I: basic mechanisms and in vivo monitoring of ROS. Circulation. 2003;108(16):1912–1916.
EganKMLawsonJAFriesS. COX-2-derived prostacyclin confers atheroprotection on female mice. Science. 2004;306(5703):1954–1957.
34.
BreimerLHMikhailidisDP. Is bilirubin a marker of vascular disease and/or cancer and is it a potential therapeutic target?CurrPharm Des. 2011;17(33):3644–3655.
